Key points:

• The European clinical trial ecosystem we see today has undergone a complete reshape which has brought with it many positive changes. This new landscape has, however, also created many issues. Complex and inconsistent requirements across Europe, unnecessary red tape and slow uptake of novel approaches are forcing companies to look outside Europe for clinical research. Europe’s global share of clinical trials continues to decline with the US outperforming Europe and countries such as Asia emerging as a major location for new clinical trials
• The location of a clinical trial is critical for patients, healthcare systems and society. Without clinical trials, patients will lose early access to innovative medicines, and for rare disease patients, trials can be the only option

To read more key points and the session summary, log in as a member or register for free using the links below.